Display options
Cite
Ruderman MA, Powell SB, Geyer MA. A Kappa Opioid Model of Atypical Altered Consciousness and Psychosis: U50488, DOI, AC90179 Effects on Prepulse Inhibition and Locomotion in Mice. J Young Investig. 2009;19(13):1-7
Ruderman, M. A., Powell, S. B., & Geyer, M. A. (2009). A Kappa Opioid Model of Atypical Altered Consciousness and Psychosis: U50488, DOI, AC90179 Effects on Prepulse Inhibition and Locomotion in Mice. Journal of young investigators, 19(13), 1-7.
Ruderman, Michael A, et al. "A Kappa Opioid Model of Atypical Altered Consciousness and Psychosis: U50488, DOI, AC90179 Effects on Prepulse Inhibition and Locomotion in Mice." Journal of young investigators vol. 19,13 (2009): 1-7.
Ruderman MA, Powell SB, Geyer MA. A Kappa Opioid Model of Atypical Altered Consciousness and Psychosis: U50488, DOI, AC90179 Effects on Prepulse Inhibition and Locomotion in Mice. J Young Investig. 2009 Jul 01;19(13):1-7. PMID: 25346645; PMCID: PMC4208663.
Copy Download .nbib Format: NLM
Share it on

J Young Investig. 2009 Jul 01;19(13):1-7.

A Kappa Opioid Model of Atypical Altered Consciousness and Psychosis: U50488, DOI, AC90179 Effects on Prepulse Inhibition and Locomotion in Mice.

Journal of young investigators

Michael A Ruderman, Susan B Powell, Mark A Geyer

Affiliations

  1. Department of Psychiatry and Neuroscience, University of California, San Diego, Department of Psychology and Biology, University of California, Santa Cruz.

PMID: 25346645 PMCID: PMC4208663

Abstract

Sensorimortor gating and locomotion are behaviors that reflect pre-attentive sensory filtering and higher order, top-down, sensory processing, respectively. These processes are thought to affect either the perception of novelty in an environment (filtering) or cognition (higher order processing), salient features of models of altered states of consciousness (ASC). Drugs with highly selective receptor affinities that produce ASC can help to establish neural correlates, pathways, and mechanisms underlying ASC. Furthermore, screening for substances that selectively reverse drug-induced sensory processing departures is valuable for development of experimental antipsychotics. This study investigated the anomalous opioid sub-type, the kappa opioid (KA) system, within the two ASC models. Significant interaction and reversal effects between KA and the serotonin/2A (5-HT2A) system - the serotonin sub-type associated with classical psychedelics - were observed in three BPM measures. These measures showed that KA activation-induced effects could be reversed by 5-HT2A deactivation. These results suggest that KA could function as an atypical antipsychotic medications and/or as a screening tool for new antipsychotic medicines. The experimental work for this study comprised dose-response and reversal experiments with drugs that activate and deactivate kappa opioid and serotonin systems in the two behavioral models for the first time in mice.

References

  1. Neuropsychopharmacology. 1990 Jun;3(3):211-8 - PubMed
  2. Neuropsychopharmacology. 1989 Dec;2(4):299-308 - PubMed
  3. J Pharmacol Exp Ther. 1992 Nov;263(2):486-93 - PubMed
  4. Prog Neuropsychopharmacol Biol Psychiatry. 1995 Dec;19(8):1239-49 - PubMed
  5. J Pharmacol. 1986 Oct-Dec;17(4):601-14 - PubMed
  6. Psychopharmacology (Berl). 1985;85(3):309-14 - PubMed
  7. Psychopharmacology (Berl). 2001 Sep;157(2):151-62 - PubMed
  8. Neuron. 2007 Feb 1;53(3):439-52 - PubMed
  9. Psychopharmacology (Berl). 1999 Apr;143(4):365-72 - PubMed
  10. Biol Psychiatry. 2005 Jun 15;57(12 ):1550-8 - PubMed
  11. Brain Res Bull. 2001 Nov 15;56(5):495-507 - PubMed
  12. J Pharmacol Exp Ther. 1999 Feb;288(2):643-52 - PubMed
  13. Trends Pharmacol Sci. 2003 Mar;24(3):107-9 - PubMed
  14. Pharmacol Biochem Behav. 1986 Jul;25(1):277-88 - PubMed
  15. J Clin Psychopharmacol. 2001 Dec;21(6):634-5 - PubMed
  16. Genes Brain Behav. 2006 Jul;5(5):423-31 - PubMed
  17. J Pharmacol Exp Ther. 1989 Aug;250(2):508-14 - PubMed
  18. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:73-9 - PubMed
  19. Psychophysiology. 1978 Jul;15(4):339-43 - PubMed
  20. Life Sci. 2004 Oct 1;75(20):2473-82 - PubMed
  21. Behav Brain Res. 2006 Sep 25;172(2):307-15 - PubMed
  22. Pharmacol Ther. 1998 Sep;79(3):231-57 - PubMed
  23. Mol Pharmacol. 2003 Sep;64(3):594-9 - PubMed

Publication Types

Grant support